Acurx Pharmaceuticals Q1 2024 Earnings Report $0.88 +0.10 (+12.20%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast Acurx Pharmaceuticals EPS ResultsActual EPS-$0.28Consensus EPS -$0.24Beat/MissMissed by -$0.04One Year Ago EPSN/AAcurx Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAcurx Pharmaceuticals Announcement DetailsQuarterQ1 2024Date5/14/2024TimeN/AConference Call ResourcesPress ReleaseACXP Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Acurx Pharmaceuticals Earnings HeadlinesAcurx Pharmaceuticals (NASDAQ:ACXP) Receives Buy Rating from HC WainwrightJanuary 13, 2025 | americanbankingnews.comAcurx receives positive EMA guidance for ibezapolstat Phase 3 programJanuary 7, 2025 | markets.businessinsider.comDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. January 21, 2025 | Crypto 101 Media (Ad)Acurx to sell 2.46M shares at $1.015 in registered direct offeringJanuary 7, 2025 | markets.businessinsider.comAcurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJanuary 7, 2025 | prnewswire.comAcurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJanuary 6, 2025 | investing.comSee More Acurx Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Acurx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acurx Pharmaceuticals and other key companies, straight to your email. Email Address About Acurx PharmaceuticalsAcurx Pharmaceuticals (NASDAQ:ACXP), a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.View Acurx Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings ICICI Bank (1/22/2025)Kinder Morgan (1/22/2025)Amphenol (1/22/2025)Abbott Laboratories (1/22/2025)Johnson & Johnson (1/22/2025)Procter & Gamble (1/22/2025)Travelers Companies (1/22/2025)Progressive (1/22/2025)GE Vernova (1/22/2025)CSX (1/23/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
